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One type of aberration of DNA found in human cancers is 
loss of heterozygosity at chromosomal loci. This loss suggests 
that inactivation of particular genes is involved in the genesis 
of cancer cells. We have analyzed tumor DNA and normal 
DNA from eight patients with malignant melanomas using 
24 polymorphic DNA probes and detected loss of heterozy-
T he genes so far known to be involved in the develop­ment of human cancers can be classified into at least two groups. Group 1 consists of activated proto-onco­genes. which produce particular proteins with abnor­mal function or in abnormal amounts. Group 2 con­
sists of so-called suppressor genes. Inactivation of particular genes 
and loss of active gene products may contribute to the genesis of 
cancer cells. 
To date. more than 40 genes have been identified as possible 
proto-oncogenes [1]. However. DNA aberrations involving activa­
tion of proto-oncogenes to oncogenes have not often been observed 
in human cancers. Furthermore. the species of proto-oncogenes in 
group 1 that display structural abnormality in human tumors are 
quite limited [1]. On the other hand. there is increasing evidence for 
the involvement of group 2 genes in the development of human 
cancers. Inactivation of particular genes has been demonstrated in 
retinoblastomas [2 -7] and Wilms's tumors [8-13] by analysis of 
loss of heterozygosity at the corresponding chromosomal loci using 
polymorphic DNA probes. Recently. loss of heterozygosity at par­
ticular chromosomal loci has also been observed in several other 
types of human cancer: small-cell carcinoma of the lung [14-16]. 
renal-cell carcinoma [17]. colorectal carcinoma [18.19]. bladder car­
cinoma [20]. breast carcinoma [21 -23]. meningioma [24]. acoustic 
neuroma [25 -27]. multiple endocrine neoplasia type I [28]. and 
rhabdomyosarcoma [29]. 
In this study. we analyzed the DNAs from patients with malig­
nant melanoma using polymorphic DNA probes and observed a 
higher frequency of loss of genes than of proto-oncogene activa­
tion. 
MATERIALS AND METHODS 
Isolation of DNA High molecular weight DNA was isolated 
from malignant melanomas by the method ofBlin and Stafford [30]. 
DNA was also prepared from peripheral leukocytes or fibroblasts of 
the same patients. DNA was also isolated from other tissues. includ­
ing the liver and muscle of autopsied cases. 
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gosity in three patients at five loci on four different chromo­
somes. These results indicate that the frequency of loss of 
heterozygosity at chromosomal loci is relatively high in ma­
lignant melanomas, but that the regions lost are not restricted 
to specific chromosomes. ] Invest Dermatol 92:280S-283S, 
1989 
Southern Blot Analysis DNA was digested with appropriate 
restriction endonucleases. and the DNA fragments obtained were 
separated by electrophoresis in 0.7% agarose gels and then trans­
ferred to nylon filters {Gene Screen Plus. Dupont, NEN Research 
Products, Boston, MA.} by the method of Southern [31]. For hybri­
dization, the filters were treated with nick-translated, (32P] labeled, 
DNA probes at 42°C for 16 h in a mixture of 50% formamide. 
6 X standard saline citrate (6 X SSe), 5 X Denhardt's solution, 10 
rnM EDTA, 0.5% sodium dodecyl sulfate {SDS}, and 100/lgjml 
dextran sulfate. The filters were washed for 30 min with two 
changes of 2 XSSC containing 1 % SDS at 65 ° C, and then with two 
changes of 0.1 X SSC at 20°C. The washed filters were exposed to 
Kodak x-ray film {XAR-5} with a Dupont Cronex intensifying 
screen at -80 ° C. After exposure, the filters were incubated in 0.4 N 
NaOH at 42°C for 30 min and then in a mixture of 0.1 X SSC. 
0.1 % SDS. and 0.2 M Tris-HCI {pH7.5} at 42°C for 30 min to 
remove the hybridized labeled probes. Such filters have been used 
for hybridization at least six times without a detectable decrease in 
signals or an increase in background hybridization. 
RESULTS 
Using 15 representative oncogene probes, we analyzed 19 samples 
of DNA from malignant melanomas obtained from surgical speci­
mens and from cell lines to search for structural aberrations involved 
in activation of proto-oncogenes. As in other human cancers, ampli­
fication or rearrangement of proto-oncogenes including H-ras, 
K-ras, N-ras, c-mye, N-mye, L-mye, myb ,fos, erhBI, erbB2,fgr,fes, raj, 
mos, and ets was rare in these malignant melanomas. We have de­
tected only amplification of the c-H-ras-l gene in one cell line SK2 
[30]. This amplified SK2 c-H-ras-l allele was also able to transform 
mouse NIH3T3 cells [31], because of T to G transversion of the 
second letter of codon 12 [32]. Other DNA samples did not show 
any transforming activity, suggesting the absence of point muta­
tional activation of c-H-ras-l, c-K-ras-2, N-ras, or erbB2 in these 
DNA. 
Because we detected only one case of structural aberration of 
proto-oncogenes, we next examined for loss of particular genes. of 
the 19 DNA samples from malignant melanomas examined for 
proto-oncogene aberration, those of the eight patients shown in 
Table I could be compared with DNAs from normal tissues of the 
same patients. The DNA samples were digested with restriction 
endonucleases and examined by Southern blotting with the 23 
polymorphic DNA probes shown in Table II. 
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Table I. Patients and Tumors Analyzed for RFLP 
Patient> Age(yr) Sex Stageb Organ' 
MM4+ 33 M III M'(Skin, melanotic) 
M'(Skin, amelanotic) 
MM8+ 52 F IV M'(Liver) 
MM9 40 F III PJ(Subungual) 
MMI0+ 59 F IV M'(Skin) 
MMI2+ 55 M IV M'(Brain) 






MM 14 8 1  F III M'(Lymph node) 
MM 15 66 M III M'(Lymph node, melanotic) 
M'(Lymph node, amelanotic) 
• +: died of melanoma. 
• Stages were defined as recommended by the UICC, International Union Against 
Cancer (1987). 
r M: metastasis. 
I P: primary. 
The results obtained on DNAs from patient MM12 analyzed 
with DNA probes for loci on the short arm of chromosome 11 (11 p) 
are shown in Fig 1. The normal DNA from the patient displayed 
restriction fragment length polymorphism (RFLP) at the loci for 
CAT, CALCA, D11S12, and HRAS1. The PTH locus was homo­
zygous. On the other hand. the DNA from the malignant mela­
noma showed loss of heterozygosity at the D11S12 and HRAS1 
loci. because the amounts of DNA fragments corresponding to al­
lele 2 of D11 S12 and allele 2 of HRAS1 were greatly reduced (Fig 
1). The residual amounts of DNA fragments observed at the posi­
tions of putatively deleted alleles might be due to appreciable quan­
tities of normal cells in the tumor. The heterozygosity at the CA T 
and CALCA loci was preserved in the tumor. 
Losses of sequences at chromosomal loci were also observed in the 
malignant melanomas of patients MM9 and MMI4. As shown in 
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Figure 1. Loss of constitutional heterozygosity at loci on chromosome 11 p 
in a malignant melanoma. DNAs from a metastatic malignant melanoma in 
the brain (T) and from peripheral leukocytes (N) of patient MM12 were 
digested with the restriction endonucleases indicated at the bottom of the 
figure. Southern blots were hybridized to 32P-labeled DNA probes for the 
CA T, CALCA, PTH, D11S12, andHRAS110ci. Numbers 1 and20n the left 
indicate the observed alleles. and C indicates the DNA fragment common to 
the alleles. 
Fig 2A,B, patients MM9 and MM 14 were heterozygous at loci for 
D13S4 and D22S1, respectively. Comparison of the normal and 
tumor DNAs from these patients revealed loss of allele 1 of D13S4 
on chromosome 13 in patient MM9 and of allele 2 of D22S1 on 
chromosome 22 in patient MM14 (Fig 2A and 2B, respectively). 
The malignant melanoma from patient MM 12 that had lost genes 
on 11 p. as shown in Fig 1, was also found to have a deletion of the 
sequence at the DXS41 locus on chromosome X. Because this male 
patient carried only one allele of DXS41, loss of the allele resulted in 
a great reduction in the corresponding DNA fragment (Fig 2C) . 
Table II summarizes the results obtained in material derived from 
the patients described above and from the other patients. Loss of 
heterozygosity was observed in malignant melanomas from three of 
eight patients at five of 82 informative chromosomal loci. The 
DNAs from more than one metastasis of patients MM4. MM 13. and 
Table II. Loss of Heterozygosity in Malignant Melanomas 
Locus MYCL ATJ D3S2 MYB MET MET D9S1 PLAU CAT CALCA PTH O11S12 
Enzyme EeaRI Pstl Mspl EeaRI Taql Mspl Taql BamHI Taql Taql Pstl Bc1l 
Chromosome 1 1 3 6 7 7 9 10 11 11 11 11 
Patient 
MM4 -. 121 12 12 12 ND' 12 12 
MM8 12 12 12 12 12 12 
MM9 12 12 12 12 12 12 12 12 
MMI0 12 12 12 
MM12 12 12 12 12 12 12 
MM13 12 12 12 12 12 ND 12 12 
MM14 12 12 12 12 12 
MM15 12 12 ND 
HRAS1 D13S3 D13S4 D14S1 O17S1 ERBA2 D18S5 D20S4 D20S5 D20S6 D22S1 DXS41 DXS43 
Pvufl Mspl Mspl EcoRI Sstl BamHI Taql Mspl Pvull Taql Bglll Pstl Pvull 
1 1  13 13 14 17 17 18 20 20 20 22 X X 
MM4 12 12 12 12 12 1 
MM8 12 12 ND 
MM9 12 2 ND 12 
MMI0 12 12 12 12 
MM12 1 12 12 12 OJ 
MM13 12 12 12 12 12 12 12 12 12 12 
MM14 12 12 12 12 12 1 
MM15 12 12 12 2 
• -: constitutional homozygosity. 
• 12: alleles present. 
, ND: not determined. 
'0: complete loss of alleles. 




























Figure 2. Loss of heterozygosity at three chromosomal loci in malignant 
melanomas. DNAs isolated from a malignant melanoma (T) and from nor­
mal tissue (N) of the patients indicated were analyzed as described in Mate­
rials and Methods. Explanations are the same as in Fig 1. 
MM15 were analyzed (Table I), but no loss of heterozygosity was 
detected. For example, the DNAs from six metastases in patient 
MM 13 showed no loss of heterozygosity at any of the 17 informa­
tive loci analyzed, suggesting that loss of heterozygosity was not a 
random phenomenon occurring during metastasis. Therefore, the 
results for only one tumor from each patient are shown in Table II. 
DISCUSSION 
We examined samples of DNA from malignant melanomas for 
aberrations of 15 representative proto-oncogenes and for loss of 
heterozygosity at 24 chromosomal loci. In these DNAs the inci­
dence of loss of heterozygosity at chromosomal loci was much 
higher than that of structural aberrations of proto-oncogenes: 82 
informative loci in DNAs from eight patients' tumors were exam­
ined, and loss of heterozygosity was observed at five loci in three 
patients, one locus in a primary melanoma, and four loci in two 
metastatic melanomas. Loss of genes was apparently not a random 
phenomenon occurring during metastasis, because six metastatic 
tumors in patient MM 13 did not show loss of heterozygosity at any 
informative locus examined. 
Karyotypic analysis of melanoma cells has revealed characteristic 
aberrations of chromosomes 1, 6, and 7 [35-38]. In this study, no 
loss of heterozygosity was observed at the five loci on the chromo­
somes examined, but the number of cases analyzed and the number 
of polymorphic DNA probes used were limited. 
We detected loss of heterozygosity in melanoma cells at loci on 
four different chromosomes, 11 p, 13, 22, and X. Three of the five 
losses were found in a brain metastasis in patient MM 12, two at the 
DllS12 and HRASl loci on IIp, and one at DXS41 on chromo­
some X. Because the order of the loci on chromosome 11 p analyzed 
is thought to be centromere-CAT-CALCA-PTH-D11 S12-
HRAS1-teiomere [37], loss of heterozygosity at the DllS12 and 
HRAS 1 loci indicates that the region lost is continuous from the 
D11S12 locus to the HRASl locus but not beyond the CALCA 
locus on chromosome 11. Loss of heterozygosity at loci on 11 p has 
been reported in several human cancers, including Wilms's tumors 
[8 -11], bladder carcinomas [20], breast carcinomas [21,23], rhab­
domyosarcomas [29], and lung carcinomas [40]. The malignant 
melanoma from patient MM 12 also showed loss of heterozygosity 
at DXS41 on chromosome X. Dracopoli et al reported loss of het­
erozygosity at X-linked loci during tumor progression in a patient 
with melanoma [41], Losses of heterozygosity at the D13S4 locus 
on chromosome 13 and at the D22S 1 locus on chromosome 22 were 
observed in a primary malignant melanoma of patient MM9 and in a 
metastatic melanoma of patient MM14, respectively. Loss of het-
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erozygosity at a locus on chromosome 13 in a malignant melanoma 
has also been reported by Dracopoli et al [41]. 
Although the frequency of loss of heterozygosity at chromo­
somal loci is relatively high, somatic mutations in DNA resulting in 
allelic losses are not restricted to specific chromosomes in malignant 
melanomas. Further data, such as those reported here, will be neces­
sary to elucidate the significance of allelic deletion at chromosomal 
loci in malignant melanomas. 
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